Some providers prefer a one-week gap between medications
The CV outcome trials (CVOT) (Figure 1) of all the GLP-1 RAs (liraglutide, semaglutide, dulaglutide, albiglutide, extended-release exenatide, and lixisenatide) (Table 1)
Large randomized clinical trials are still needed before doctors can recommend these medicines for psychiatric conditions
Patients considering either option should discuss: Long-term expectations Cost considerations Side-effect management Nutrition support Physical activity plans Ongoing monitoring GLP-1 medications work best as part of a broader metabolic health strategy rather than as isolated quick fixes
That would still mean a price hike for Hims & Hers customers, since even matching Novo Nordisk's rates would result in patients paying more than before
Injections typically produce faster satiety effects and allow providers to adjust doses more precisely than oral tablets